Healthy Clinical Trial
Official title:
Improvement of Use Dependent Plasticity in Chronic Stroke Patients
This study will examine the role of an amphetamine in improving the effect that electrical
nerve stimulation has over brain flexibility associated with motor training in patients who
experienced a stroke more than 1 year before. Chronic stroke is the main cause of long-term
disability among adults. Previous studies have shown that electrical stimulation given over
the skin may improve patients' recovery of motor function. Furthermore, it is known that
amphetamines can improve the effects of sensory stimulation such as touch. Use dependent
plasticity refers to a process in which the performance of simple, repetitive finger
movements leads to encoding the details of those actions in the primary motor cortex of the
brain. Plasticity in this sense refers to the capacity for change in the brain.
Patients 18 years of age and older who have had a stroke, who have no history of other
neurological and psychiatric illnesses, and who are able to contrite and perform simple
attentional tasks and other tasks may be eligible for this study. There will also be healthy
participants as a control group.
Participants will have an electrocardiogram. They will also go through a practice session of
about 3 hours in which they become familiar with the different tasks required in the study:
motor training, pinch force, and the Jebsen-Taylor Test-which requires doing as fast as
possible actions that include writing, lifting small common objects, turning pages, or
lifting light or heavy objects. Then during the study, patients will be involved in a variety
of sessions:
- Motor training alone for about 3 hours.
- Motor training, amphetamine (or placebo), and electrical stimulation for about 6 hours.
- Motor training, amphetamine, and no electrical stimulation for about 6 hours.
A magnetic resonance imagining (MRI) scan will be done. Patients will lie still on a table
that can slide in and out of a metal cylinder surrounded by a strong magnetic field. Scanning
time varies from 20 minutes to 3 hours, with most scans lasting between 45 and 90 minutes.
Patients may be asked to lie still for up to 60 minutes at a time. As the scanner takes
pictures, there will be loud knocking noises, and the patients will wear earplugs to muffle
the sound. Patients will be able to communicate with the MRI staff at all times during the
scan and may ask to be moved out of the machine at any time.
During another procedure called transcranial magnetic stimulation (TMS), a wire coil will be
held over the scalp. A brief electrical current will be passed through the coil, creating a
magnetic pulse that stimulates the brain. Patients will hear a click and may feel a pulling
sensation on the skin under the coil. There may be muscle twitches of the face, arm, or leg.
Patients may be asked to tense certain muscles slightly or perform other simple actions so
that the coil can be positioned appropriately. The stimulation is usually not painful,
although sometimes strong contractions of the scalp muscles can cause discomfort or a
headache. Patients can ask to have the procedure discontinued at any time.
For the electrical stimulation procedure, three pairs of electrodes will be placed on the
skin. A quite brief pulse of current will pass between the electrodes, creating the
electrical field that activates the brain. Patients will feel a brief stinging around the
electrodes. Regarding the amphetamine, patients will take it orally on up to four different
occasions. Usually they will take 10 mg of Dexedrin before testing.
OBJECTIVES:
There is no universally accepted strategy to promote recovery of motor function after chronic
stroke, the main cause of long-term disability among adults. It is desirable to develop
strategies to enhance motor training in this patient group. A recent study in stroke patients
and healthy volunteers demonstrated that somatosensory nerve stimulation prior to motor
training leads to improvements in use-dependent plasticity (UDP), a process thought to
underlie recovery of motor function after brain injury (Sawaki et al., unpublished
information). Interestingly, the effects of sensory input on cortical plasticity can be
enhanced by a single dose of amphetamine. The objective of this protocol is to further
enhance the effect that somatosensory nerve stimulation has on motor training by means of
pre-medication with amphetamine. This effect over motor training will be measured by the
magnitude of training-induced UDP. Our hypothesis is that the amphetamine-enhanced effects of
somatosensory nerve stimulation will increase the magnitude of training-induced UDP.
STUDY POPULATION:
We plan to study 24 patients with chronic strokes and 24 healthy age- and gender matched
normal volunteers.
DESIGN:
All subjects will participate in 5 different randomized sessions on separate days. The first
session will be a familiarization with the behavioral tasks. A second experiment will consist
of training with no further interventions to obtain baseline UDP changes. In another two
sessions, subjects will be premedicated in a blind manner with amphetamine or placebo before
administration of somatosensory nerve stimulation followed by motor training to induce UDP.
In the last experiment, the participants will be premedicated with amphetamine and will be
exposed to sham somatosensory stimulation prior to the motor training to induce UDP.
OUTCOME MEASURES:
Primary outcome measure will be the magnitude of UDP (training-induced changes in
transcranial magnetic stimulation-evoked kinematic responses). Secondary outcome measures are
pinch force; and a functional measure of activities of daily life (ADL): Jebsen-Tailor-Test.
To better understand the mechanisms underlying the proposed behavioral gains, we will use TMS
to identify changes in corticomotor excitability.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |